Y-mabs Therapeutics, Inc. (NASDAQ: YMAB) has announced the appointment of Dr. Mary Tagliaferri to its board of directors, effective February 29, 2024. Dr. Tagliaferri brings nearly 30 years of biopharmaceutical industry experience and oncology therapeutic development expertise to the Y-mabs board of directors.
Dr. Tagliaferri is currently the Chief Medical Officer and Senior Vice President of Nektar Therapeutics, a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing innovative medicines in the field of immunotherapy. She has been responsible for numerous clinical studies evaluating novel therapeutics in oncology and played a key role in establishing strategic partnerships.
Previously, Dr. Tagliaferri served as Chief Medical Officer for Kanglaite-USA and was a co-founder, president, and board member of Bionovo, Inc. She currently serves on the board of Enzo Biochem, Inc. and was a board member of Rayzebio, Inc. until its acquisition by Bristol-Myers Squibb in 2024.
Dr. Tagliaferri has a distinguished career, having been honored as an eminent woman leader in healthcare by Inc. Magazine in 2023, named to the Women Who Lead in Life Sciences and Most Influential Women in Business lists by the San Francisco Business Times in 2019, and recognized as Woman of the Year in 2012 by the State of California, Assembly District 14. She has also been lead author or contributor to approximately 90 peer-reviewed journal publications.
Y-mabs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include the investigational self-assembly disassembly (SADA) pretargeted radioimmunotherapy platform and bispecific antibodies generated using the Y-Biclonal platform. The company's product pipeline includes the anti-GD2 therapy Danyelza® (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy.
Today the company's shares have moved -2.9% to a price of $18.15. For the full picture, make sure to review Y-mAbs Therapeutics's 8-K report.
